Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUR103 Calcium in Advanced Neuroendocrine Tumours
NCT07640737Phase 2Not yet recruiting
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AUR103 in Neuroendocrine Neoplasm (NEN), sponsored by Aurigene Pharmaceutical Services Limited. Primary endpoint: Objective Response Rate at Cycle 12. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
AUR103
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT07640737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640737.